J Gynecol Oncol.  2013 Oct;24(4):330-335. 10.3802/jgo.2013.24.4.330.

Clinical outcome of 31 patients with primary malignant melanoma of the vagina

• Huang Q
• Huang H
• Wan T
• Deng T
• Liu J

• KMID: 2177874
• DOI: http://doi.org/10.3802/jgo.2013.24.4.330

Abstract

OBJECTIVE
To investigate the clinical characteristics of and prognostic factors for primary malignant melanoma of the vagina.
METHODS
Clinical data from 31 patients treated for primary malignant melanoma of the vagina at the Sun Yat-sen University Cancer Center between March 1970 and June 2005 were retrospectively analyzed.
RESULTS
The median age was 58 years (range, 18 to 73 years), and the main symptoms reported were vaginal bleeding and vaginal discharge. Most tumors were of the nodular type and classified as stage I according to International Federation of Gynecology and Obstetrics staging criteria. Surgery was performed on 22 patients, chemotherapy was administered to 7 patients, and immunotherapy was administered to 19 patients. Recurrent tumors developed in 11 patients (35.5%) during a median follow-up period of 20.2 months (range, 1 month to 18 years). The 5-year overall survival rate was 32.3%. Univariate analysis revealed that macroscopic tumor growth and the treatment method significantly affected survival outcome (p=0.039 and p<0.001, respectively), whereas the radicality of surgery did not (p=0.296). Multivariate analysis revealed that macroscopic tumor growth (hazard ratio [HR], 4.1; 95% confidence interval [CI], 1.4 to 12.1; p=0.010) and treatment method (HR, 0.3; 95% CI, 0.1 to 0.9; p=0.025) were independent prognostic factors for overall survival.
CONCLUSION
Patients with primary vaginal melanoma have a poor prognosis. Macroscopic tumor growth and treatment method are prognostic factors for primary malignant melanoma of the vagina.

Keyword

Immunotherapy; Malignant melanoma; Surgical treatment; Vaginal malignancies

MeSH Terms

Follow-Up Studies
Gynecology
Humans
Immunotherapy
Melanoma
Multivariate Analysis
Obstetrics
Prognosis
Retrospective Studies
Solar System
Survival Rate
Uterine Hemorrhage
Vagina
Vaginal Discharge

Reference

1. Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol. 1994; 171:1225–1230.

2. FIGO (International Federation of Gynecology and Obstetrics) 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; 95:Suppl 1. S1–S257.

3. Gupta D, Malpica A, Deavers MT, Silva EG. Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 2002; 26:1450–1457.

4. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, et al. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010; 116:1358–1365.

5. Cobellis L, Calabrese E, Stefanon B, Raspagliesi F. Malignant melanoma of the vagina: a report of 15 cases. Eur J Gynaecol Oncol. 2000; 21:295–297.

6. Reid GC, Schmidt RW, Roberts JA, Hopkins MP, Barrett RJ, Morley GW. Primary melanoma of the vagina: a clinicopathologic analysis. Obstet Gynecol. 1989; 74:190–199.

7. Ragnarsson-Olding B, Johansson H, Rutqvist LE, Ringborg U. Malignant melanoma of the vulva and vagina: trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer. 1993; 71:1893–1897.

8. Van Nostrand KM, Lucci JA 3rd, Schell M, Berman ML, Manetta A, DiSaia PJ. Primary vaginal melanoma: improved survival with radical pelvic surgery. Gynecol Oncol. 1994; 55:234–237.

9. Borazjani G, Prem KA, Okagaki T, Twiggs LB, Adcock LL. Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases. Gynecol Oncol. 1990; 37:264–267.

10. Neven P, Shepherd JH, Masotina A, Fisher C, Lowe DG. Malignant melanoma of the vulva and vagina: a report of 23 cases presenting in a 10-year period. Int J Gynecol Cancer. 1994; 4:379–383.

11. Raber G, Mempel V, Jackisch C, Schneider HP. Clinical aspects of primary malignant melanoma of the vagina. Zentralbl Gynakol. 1993; 115:416–422.

12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer;2010.

13. McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC 2nd, Urist MM, et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg. 2010; 252:460–465.

14. Davidson T, Kissin M, Westbury G. Vulvo-vaginal melanoma: should radical surgery be abandoned? Br J Obstet Gynaecol. 1987; 94:473–476.

15. Konstadoulakis MM, Ricaniadis N, Driscoll DL, Karakousis CP. Malignant melanoma of the female genital system. Eur J Surg Oncol. 1994; 20:141–145.

16. Miner TJ, Delgado R, Zeisler J, Busam K, Alektiar K, Barakat R, et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol. 2004; 11:34–39.

17. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control. 2002; 9:16–21.

18. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17:2105–2116.

19. Schadendorf D, Vaubel J, Livingstone E, Zimmer L. Advances and perspectives in immunotherapy of melanoma. Ann Oncol. 2012; 23:Suppl 10. x104–x108.